Price
CHART BY
Frequently asked questions
What is iBio's market capitalization?
The market capitalization of iBio is $11.06M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for iBio?
iBio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.335. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for iBio's stock?
Currently, 3 analysts cover iBio's stock, with a consensus target price of $4.867. Analyst ratings provide insights into the stock's expected performance.
What is iBio's revenue over the trailing twelve months?
Over the trailing twelve months, iBio reported a revenue of $375.00K.
What is the EBITDA for iBio?
iBio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$15.69M. EBITDA measures the company's overall financial performance.
What is the free cash flow of iBio?
iBio has a free cash flow of -$15.77M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does iBio have, and what sector and industry does it belong to?
iBio employs approximately 19 people. It operates in the Health Care sector, specifically within the Other Pharmaceuticals industry.
What is the free float of iBio's shares?
The free float of iBio is 15.30M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $11.06M
- EPS (TTM)
- -$2.335
- Free Float
- 15.30M
- Revenue (TTM)
- $375.00K
- EBITDA (TTM)
- -$15.69M
- Free Cashflow (TTM)
- -$15.77M
Pricing
- 52W span
- $0.636$6.89
Analyst Ratings
The price target is $4.867 and the stock is covered by 3 analysts.
Buy
3
Hold
0
Sell
0
Information
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.
- Employees
- 19
- Industries
- Other Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US4510337086
- Primary Ticker
- IBIO
Fundamentals & EOD data from FactSet